News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Selecta Biosciences, Inc. Announces Successful Pre-Clinical Study Of SEL-201 As An Antigen-Specific Immune Tolerance Treatment For Patients Receiving Factor VIII Therapy


12/9/2013 9:12:04 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WATERTOWN, Mass.--(BUSINESS WIRE)--Selecta Biosciences, Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune tolerance treatments, today announced that data from a pre-clinical proof of concept study in Factor VIII-deficient mice were presented in a poster presentation at the 2013 American Society for Hematology (ASH) International Conference in New Orleans. SEL-201 demonstrated the ability to induce immune tolerance in a model of hemophilia A, showing that SEL-201 has the potential to serve as an adjunct therapy to avoid harmful neutralizing antibody response to Factor VIII treatment severely affecting hemophilia A patients.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES